fasudil has been researched along with Lung Neoplasms in 8 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After treatment to NCI-H446 small cell lung cancer cells with Fasudil, a Rho-kinase inhibitor, cell biological behaviors were observed." | 1.38 | The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. ( Di, J; Liu, J; Lu, J; Shi, W; Yang, X; Zhang, S; Zhang, Y, 2012) |
| "Fasudil is a kind of Rho kinase inhibitor." | 1.37 | Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549. ( Li, Z; Nong, L; Ren, J; Wu, G; Zhang, R; Zhang, Z; Zhu, F, 2011) |
| "Treatment with fasudil inhibited the growth of 95-D cells in a dose-dependent manner, and the IC50 of fasudil was approximately 0." | 1.36 | The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells. ( Liu, Y; Tian, D; Yang, X; Zong, Z, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Klaeger, S | 1 |
| Heinzlmeir, S | 1 |
| Wilhelm, M | 1 |
| Polzer, H | 1 |
| Vick, B | 1 |
| Koenig, PA | 1 |
| Reinecke, M | 1 |
| Ruprecht, B | 1 |
| Petzoldt, S | 1 |
| Meng, C | 1 |
| Zecha, J | 1 |
| Reiter, K | 1 |
| Qiao, H | 1 |
| Helm, D | 1 |
| Koch, H | 1 |
| Schoof, M | 1 |
| Canevari, G | 1 |
| Casale, E | 1 |
| Depaolini, SR | 1 |
| Feuchtinger, A | 1 |
| Wu, Z | 1 |
| Schmidt, T | 1 |
| Rueckert, L | 1 |
| Becker, W | 1 |
| Huenges, J | 1 |
| Garz, AK | 1 |
| Gohlke, BO | 1 |
| Zolg, DP | 1 |
| Kayser, G | 1 |
| Vooder, T | 1 |
| Preissner, R | 1 |
| Hahne, H | 1 |
| Tõnisson, N | 1 |
| Kramer, K | 1 |
| Götze, K | 1 |
| Bassermann, F | 1 |
| Schlegl, J | 1 |
| Ehrlich, HC | 1 |
| Aiche, S | 1 |
| Walch, A | 1 |
| Greif, PA | 1 |
| Schneider, S | 1 |
| Felder, ER | 1 |
| Ruland, J | 1 |
| Médard, G | 1 |
| Jeremias, I | 1 |
| Spiekermann, K | 1 |
| Kuster, B | 1 |
| Guerra, FS | 1 |
| Oliveira, RG | 1 |
| Fraga, CAM | 1 |
| Mermelstein, CDS | 1 |
| Fernandes, PD | 1 |
| Xia, Y | 1 |
| Cai, XY | 1 |
| Fan, JQ | 1 |
| Zhang, LL | 1 |
| Ren, JH | 2 |
| Li, ZY | 2 |
| Zhang, RG | 1 |
| Zhu, F | 2 |
| Wu, G | 3 |
| Yang, X | 3 |
| Liu, Y | 1 |
| Zong, Z | 1 |
| Tian, D | 1 |
| Zhang, Z | 2 |
| Li, Z | 1 |
| Zhang, R | 1 |
| Ren, J | 1 |
| Nong, L | 2 |
| Zhang, Y | 2 |
| Wang, S | 1 |
| Shi, W | 2 |
| Di, J | 1 |
| Zhang, S | 1 |
| Lu, J | 1 |
| Liu, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 other studies available for fasudil and Lung Neoplasms
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinas | 2017 |
ROCK inhibition with Fasudil induces beta-catenin nuclear translocation and inhibits cell migration of MDA-MB 231 human breast cancer cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; beta Catenin; Carcinoma; Cell | 2017 |
The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; A549 Cells; Animals; Antigens, CD; Carcinoma, Non-Sma | 2019 |
The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; ATP-Binding Cassette Transporters; Cell Line, Tumor; | 2010 |
Rho kinase inhibitor fasudil suppresses migration and invasion though down-regulating the expression of VEGF in lung cancer cell line A549.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Blotting, Western; Cell Line, | 2011 |
Effect of fasudil on growth, adhesion, invasion, and migration of 95D lung carcinoma cells in vitro.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Antineoplastic Agents; Carcinoma; Cell Adhesion; Cell | 2010 |
Fasudil inhibits lung carcinoma-conditioned endothelial cell viability and migration.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adenocarcinoma; Adenocarcinoma of Lung; Angiogenesis | 2012 |
The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Apoptosis; Caspase 3; Cell Adhesion; Cell Line, Tumor | 2012 |